ANAPTYSBIO, INC 8-K

What Happened AnaptysBio, Inc. (ANAB) filed an 8-K on January 9, 2026 saying it will present at the 2026 J.P. Morgan Healthcare Conference on January 11, 2026 and is disclosing preliminary, unaudited financial information. The company expects to report cash and cash equivalents and investments of approximately $310 million as of December 31, 2025. AnaptysBio noted its audited financial statements for the year ended December 31, 2025 are not yet complete, so the figures are estimates subject to closing procedures and audit adjustments.

Key Details

• Preliminary liquidity: cash and cash equivalents plus investments of approximately $310 million as of December 31, 2025.
• Timing and filing: 8-K filed January 9, 2026; Presentation to be delivered January 11, 2026 at the J.P. Morgan Healthcare Conference.
• Disclosure nature: figures are unaudited estimates and may differ materially from final audited results.
• Public materials: the corporate presentation was furnished as Exhibit 99.1 to the 8-K; the filing was signed by Chief Legal Officer Eric Loumeau.

Why It Matters Cash and investments are a key indicator of a biotech company's near-term financial flexibility—$310M (preliminary) gives investors a snapshot of AnaptysBio’s available liquidity entering 2026. However, because the information is preliminary and unaudited, investors should wait for the company’s audited 2025 financial statements and any further disclosures for a complete and final picture of results and runway. The furnished JP Morgan presentation provides additional context but does not replace audited financial statements.